ABSTRACT
DNA vaccines have proved to be potential candidates to be considered as a part of active immunity. These latest generation genetic tools have solved the problems associated with the traditional vaccines. However, there are number of infectious diseases like AIDS, Malaria and Tuberculosis against which no DNA vaccine has been established. This review describes multiple DNA vaccine applications and delivery systems for DNA antigen. Future strategies to improve the efficacy of DNA vaccine like route of administration and novel adjuvants are also discussed
Subject(s)
Immunization/methods , Vaccination , Immunity, Cellular , Antibodies, ViralABSTRACT
The aim is to evaluate the effect of ciprofloxacin and chloramphenicol on anti-BSA antibody production triggered by bovine albumin encapsulated in non-ionic surfactant vesicle, niosomes. Reverse phase evaporation method was adopted to entrap the antigen in colloidal carrier composed of Span 80 and Span 85 followed by simultaneous characterization for particle size, entrapment efficiency and in vitro release. The protein content was determined by Bradford method using UV Visible Spectrophotometer at 595 nm. Humoral immune response was measured in terms of systemic IgG antibody titre by ELISA method. Experimental data indicated that 7 : 3 molar ratio of Span 80 and cholesterol based niosomal formulation possessed maximum (39.8 +/- 2.9)% of soluble protein. Ciprofloxacin markedly (P < 0.05) decreased the antibody titre. In contrast, chloramphenicol did not reduce the antibody titre significantly in comparison to control group (P > 0.05). It is necessary to explore the effect of a vaccine antigen when a candidate is medicated with a therapeutic agent, which might help in programming a new drug management and vaccination programme.